Lorena San Miguel

Mrs. Lorena San Miguel

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2023 in BMC Medicine
Verified
Journal Article
Open access
PDF file
VFVibeke Fosse
Vibeke Fosse
EOEmanuela Oldoni
Emanuela Oldoni
FBFlorence Bietrix
Florence Bietrix
Alfredo BudillonAlfredo Budillon
Alfredo Budillon
EDEvangelos P. Daskalopoulos
Evangelos P. Daskalopoulos
TTTeresa Torres
Teresa Torres
Background: Personalised medicine is a medical model that aims to provide tailor-made prevention and treatment strategies for defined groups of individuals. The concept brings new challenges to the translational step, both in clinical relevance and validity of models. We have developed a set of recommendations aimed at improving the robustness of preclinical methods in translational research for personalised medicine. Methods: These recommendations have been developed following four main steps: (1) a scoping review of the literature with a gap analysis, (2) working sessions with a wide range of experts in the field, (3) a consensus workshop, and (4) preparation of the final set of recommendations. Results: Despite the progress in developing innovative and complex preclinical model systems, to date there are fundamental deficits in translational methods that prevent the further development of personalised medicine. The literature review highlighted five main gaps, relating to the relevance of experimental models, quality assessment practices, reporting, regulation, and a gap between preclinical and clinical research. We identified five points of focus for the recommendations, based on the consensus reached during the consultation meetings: (1) clinically relevant translational research, (2) robust model development, (3) transparency and education, (4) revised regulation, and (5) interaction with clinical research and patient engagement. Here, we present a set of 15 recommendations aimed at improving the robustness of preclinical methods in translational research for personalised medicine. Conclusions: Appropriate preclinical models should be an integral contributor to interventional clinical trial success rates, and predictive translational models are a fundamental requirement to realise the dream of personalised medicine. The implementation of these guidelines is ambitious, and it is only through the active involvement of all relevant stakeholders in this field that we will be able to make an impact and effectuate a change which will facilitate improved translation of personalised medicine in the future.

6 September 2017 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
NBNadia Benahmed
Nadia Benahmed
LMLorena San Miguel
Lorena San Miguel
CDCarl Devos
Carl Devos
NFNicolas Fairon
Nicolas Fairon
WCWendy Christiaens
Wendy Christiaens
There is an international trend to shorten the postpartum length of stay in hospitals, driven by cost containment, hospital bed availability and a movement toward the ‘demedicalization’ of birth. The aim of this systematic literature review is to determine how early postnatal discharge policies from hospitals could affect health outcomes after vaginal delivery for healthy mothers and term newborns. A search for systematic reviews, meta-analyses, and primary studies was carried out in OVID MEDLINE, Embase, CINAHL, Econlit and the Cochrane Library (Cochrane Database of Systematic Reviews, DARE and HTA databases). The AMSTAR checklist was used for the quality appraisal of systematic reviews. The quality of the retrieved studies was assessed by the Cochrane Collaboration’s tools. The level of evidence was appraised using the GRADE system. Seven RCTs and two additional observational studies were found but no comprehensive economic evaluation. Despite variation in the definition of early discharge, the authors of the included studies, concerning early discharge and conventional length of stay, reported no statistical difference in maternal and neonatal morbidity, maternal and neonatal readmission rates, infant mortality, newborn weight gain, neonatal hyperbilirubinemia, or breastfeeding rates. The authors reported conflicting results regarding postpartum depression and competence of mothering, ranging from no difference according to length of stay to better results for early discharge. The level of evidence of the vast majority of outcomes was rated as low to very low. Because of the lack of robust clinical evidence and full economic evaluations, the current data neither support nor discourage the widespread use of early postpartum discharge. Before implementing an early discharge policy, Western countries with longer length of hospital stay may benefit from testing shorter length of stay in studies with an appropriate design. The issue of cost containment in implementing early discharge and the potential impact on the current and future health of the population exemplifies the need for publicly funded clinical trials in such public health area. Finally, trials testing the range of out-patient interventions supporting early discharge are needed in Western countries which implemented early discharge policies in the past.

6 May 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
CSCecilia Superchi
Cecilia Superchi
FBFlorie Brion Bouvier
Florie Brion Bouvier
CGChiara Gerardi
Chiara Gerardi
MCMontserrat Carmona
Montserrat Carmona
LMLorena San Miguel
Lorena San Miguel
RPRaphaël Porcher
Raphaël Porcher
Objective Personalised medicine (PM) allows treating patients based on their individual demographic, genomic or biological characteristics for tailoring the ‘right treatment for the right person at the right time’. Robust methodology is required for PM clinical trials, to correctly identify groups of participants and treatments. As an initial step for the development of new recommendations on trial designs for PM, we aimed to present an overview of the study designs that have been used in this field. Design Scoping review. Methods We searched (April 2020) PubMed, Embase and the Cochrane Library for all reports in English, French, German, Italian and Spanish, describing study designs for clinical trials applied to PM. Study selection and data extraction were performed in duplicate resolving disagreements by consensus or by involving a third expert reviewer. We extracted information on the characteristics of trial designs and examples of current applications of these approaches. The extracted information was used to generate a new classification of trial designs for PM. Results We identified 21 trial designs, 10 subtypes and 30 variations of trial designs applied to PM, which we classified into four core categories (namely, Master protocol, Randomise-all, Biomarker strategy and Enrichment). We found 131 clinical trials using these designs, of which the great majority were master protocols (86/131, 65.6%). Most of the trials were phase II studies (75/131, 57.2%) in the field of oncology (113/131, 86.3%). We identified 34 main features of trial designs regarding different aspects (eg, framework, control group, randomisation). The four core categories and 34 features were merged into a double-entry table to create a new classification of trial designs for PM. Conclusions A variety of trial designs exists and is applied to PM. A new classification of trial designs is proposed to help readers to navigate the complex field of PM clinical trials.

1 November 2015 in Journal of Comparative Effectiveness Research
Verified
Journal Article
Closed access
LMLorena San Miguel
Lorena San Miguel
FHFrank Hulstaert
Frank Hulstaert
Background: Economic evaluations of companion diagnostics often fail to include the impact that tests have on the overall economic value of test–drug combinations. Methods: To illustrate the importance of test accuracy on the cost–effectiveness of companion diagnostics by means of examples. Data were extracted from the literature. Results: The accuracy of a test and in particularly its specificity, is often more influential on the overall cost–effectiveness results than the price of the test. Specificity becomes more crucial when prevalence of the biomarker is low. Multiple, simultaneous testing faces specific challenges regarding its overall specificity. Conclusion: This article opens a discussion on some fundamental points linked to economic evaluations of test–therapy combinations.

1 January 2017
Verified
Book
Closed access
SGSophie Gerkens
Sophie Gerkens
MNMattias Neyt
Mattias Neyt
LMLorena San Miguel
Lorena San Miguel
IVImgard Vinck
Imgard Vinck
NTNancy Thiry
Nancy Thiry
ICIrina Cleemput
Irina Cleemput
LIST OF FIGURES 3 -- LIST OF TABLES .3 -- LIST OF ABBREVIATIONS 4 -- SCIENTIFIC REPORT .6 -- 1 INTRODUCTION 6 -- 1.1 BACKGROUND 6 -- 1.2 STUDY OBJECTIVES AND RESEARCH QUESTIONS 7 -- 1.3 A DIFFICULT PROCESS DUE TO DATA CONFIDENTIALITY AND THREAT OF LEGAL PROCEEDINGS .7 -- 1.4 A RAPID LOOK AT THE EXISTING TAXONOMY 8 -- 2 A REVIEW OF THE LITERATURE ON MANAGED ENTRY AGREEMENTS: WHAT CAN BE LEARNED FROM THE CURRENT EUROPEAN EXPERIENCE? 11 -- 2.1 INTRODUCTION .11 -- 2.2 METHODS 11 -- 2.3 RESULTS 16 -- 2.3.1 Strengths of MEAs 16 -- 2.3.2 Weaknesses/Challenges of MEAs 18 -- 2.3.3 What products should be the target of MEAs 24 -- 2.3.4 Evaluation process for MEAs .24 -- 2.3.5 Checklists for evaluating the need for a MEA or the impact of an already established MEA 30 -- 2.4 LIMITATIONS 33 -- 3 DESCRIPTION OF THE LEGISLATION 34 -- 3.1 INTRODUCTION .34 -- 3.2 METHOD .34 -- 3.3 MARKET AUTHORIZATION, PRICING AND REIMBURSEMENT IN BELGIUM (FOR BOTH OUTPATIENTS AND INPATIENTS PHARMACEUTICALS) 34 -- 3.3.1 Market authorization 34 -- 3.3.2 Price setting 34 -- 3.3.3 The reimbursement procedure 35 -- 3.3.4 Specificities of orphan drugs 39 -- 3.4 EVOLUTION OF THE LEGISLATION ON MEA IN BELGIUM .40 -- 3.4.1 Situation from January 2010 until July 2014 41 -- 3.4.2 Situation from July 2014 41 -- 3.4.3 The negotiation process 42 -- 3.4.4 The convention 43 -- 3.4.5 Process at the end of the convention .43 -- 3.5 NO REGULATION OF MEAS IN A EUROPEAN CONTEXT 44 -- 4 ANALYSIS OF THE BELGIAN PROCESS FOR MEA: WHAT LESSONS CAN BE LEARNED FROM THE BELGIAN EXPERIENCE? 45 -- 4.1 INTRODUCTION .45 -- 4.2 METHOD .45 -- 4.3 RESULTS 47 -- 4.3.1 Description of the convention procedure .47 -- 4.3.2 The evaluation by the CTG-CRM .51 -- 4.3.3 Analysis of approved conventions 53 -- 4.3.4 Analysis of expired conventions 58 -- 4.3.5 Impact on the health care budget for pharmaceuticals .60 -- 5 STAKEHOLDER CONSULTATION .61 -- APPENDIX .62 -- REFERENCES .64

1 January 2014
Verified
Book
Closed access
NBNadia Benahmed
Nadia Benahmed
CDCarl Devos
Carl Devos
LMLorena San Miguel
Lorena San Miguel
IVImgard Vinck
Imgard Vinck
LVLiesbeth Vankelst
Liesbeth Vankelst
WCWendy Christiaens
Wendy Christiaens